<sup>64</sup>Cu-DOTHA<sub>2</sub>-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window

Prostate cancer imaging and late-stage management can be improved with prostate-specific membrane antigen (PSMA)-targeting radiotracers. We developed a PSMA positron emission tomography (PET) radiotracer, DOTHA<sub>2</sub>-PSMA radiolabeled with <sup>64</sup>Cu (T<sub>1...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Pharmaceuticals
المؤلفون الرئيسيون:	Marie-Christine Milot, Ophélie Bélissant Benesty, Véronique Dumulon-Perreault, Samia Ait-Mohand, Patrick O. Richard, Étienne Rousseau, Brigitte Guérin
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2022-08-01
الموضوعات:	copper-64 DOTHA<sub>2</sub> chelator PSMA prostate cancer PET imaging theranostic approaches
الوصول للمادة أونلاين:	https://www.mdpi.com/1424-8247/15/8/996

مواد مشابهة

Theranostic 64Cu-DOTHA2-PSMA allows low toxicity radioligand therapy in mice prostate cancer model
حسب: Marie-Christine Milot, وآخرون
منشور في: (2023-01-01)

Single-Center Comparison of [<sup>64</sup>Cu]-DOTAGA-PSMA and [<sup>18</sup>F]-PSMA PET–CT for Imaging Prostate Cancer
حسب: Siroos Mirzaei, وآخرون
منشور في: (2021-10-01)

Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET Imaging
حسب: Jason P. Meier, وآخرون
منشور في: (2025-06-01)

Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System
حسب: Zsófia Sára Mikó, وآخرون
منشور في: (2024-10-01)

Preclinical Theranostic Profiling of [<sup>64</sup>Cu]Cu-Acetate in Prostate Cancer
حسب: Sadaf Ghanaatgar Kasbi, وآخرون
منشور في: (2025-10-01)

[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
حسب: Ute Hennrich, وآخرون
منشور في: (2021-07-01)

Optimized <sup>68</sup>Ga-Labeled Urea-Based PSMA-Targeted PET Tracers for Prostate Cancer
حسب: Yitian Wu, وآخرون
منشور في: (2022-08-01)

[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
حسب: Ute Hennrich, وآخرون
منشور في: (2022-10-01)

Advances in PSMA theranostics
حسب: Thomas M. Jeitner, وآخرون
منشور في: (2022-08-01)

A Targeted Radiotheranostic Agent for Glioblastoma: [<sup>64</sup>Cu]Cu-NOTA-TP-c(RGDfK)
حسب: Alireza Mirzaei, وآخرون
منشور في: (2025-08-01)

Current status of PSMA-targeted imaging and therapy
حسب: Hui Wang, وآخرون
منشور في: (2024-01-01)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
حسب: Suzanne van der Gaag, وآخرون
منشور في: (2022-11-01)

Total Tumor Volume on <sup>18</sup>F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with <sup>225</sup>Ac-PSMA-I&T
حسب: Lena M. Unterrainer, وآخرون
منشور في: (2022-04-01)

Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer
حسب: Jan Heilinger, وآخرون
منشور في: (2023-09-01)

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
حسب: Mathieu Gaudreault, وآخرون
منشور في: (2023-03-01)

TREATMENT OF REFRACTORY MULTIPLE MYELOMA WITH PSMA-177LU: A CASE REPORT
حسب: Kaique M. Amaral, وآخرون
منشور في: (2024-04-01)

<sup>68</sup>Ga-PSMA PET/CT in Recurrent Prostate Cancer after Radical Prostatectomy Using PSMA-RADS Version 2.0
حسب: Gabriele Masselli, وآخرون
منشور في: (2024-06-01)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
حسب: Florian Rosar, وآخرون
منشور في: (2022-05-01)

Preclinical and clinical evaluation of [64Cu]Cu-PSMA-Q PET/CT for prostate cancer detection and its comparison with [18F]FDG imaging
حسب: Fei Chen, وآخرون
منشور في: (2025-04-01)

Therapeutic Efficacy of <sup>177</sup>Lu-Labeled A20FMDV2 Peptides Targeting α<sub>ν</sub>β<sub>6</sub>
حسب: Truc Thao Huynh, وآخرون
منشور في: (2022-02-01)

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
حسب: Louise Emmett, وآخرون
منشور في: (2017-03-01)

Preparation and Biological Evaluation of [<sup>99m</sup>Tc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer
حسب: Di Xiao, وآخرون
منشور في: (2020-11-01)

PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches
حسب: Vinh Ngoc Bui, وآخرون
منشور في: (2023-11-01)

Comparison of the Effects of DOTA and NOTA Chelators on <sup>64</sup>Cu-Cudotadipep and <sup>64</sup>Cu-Cunotadipep for Prostate Cancer
حسب: Inki Lee, وآخرون
منشور في: (2023-08-01)

[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [<sup>18</sup>F]PSMA-1007 Imaging
حسب: Moritz B. Bastian, وآخرون
منشور في: (2024-10-01)

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with <sup>177</sup>Lu-PSMA and Combined <sup>225</sup>Ac- and <sup>177</sup>Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation
حسب: Thomas Langbein, وآخرون
منشور في: (2022-08-01)

Analysis of Pros and Cons in Using [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer
حسب: Costantina Maisto, وآخرون
منشور في: (2022-06-01)

Multimodal Characterization of a PSMA-Positive Thyroid Nodule Using <sup>68</sup>Ga-PSMA and <sup>124</sup>Iodine PET/US Fusion Imaging
حسب: Martin Freesmeyer, وآخرون
منشور في: (2022-02-01)

High Prognostic Value of <sup>68</sup>Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry
حسب: Donatello Gasparro, وآخرون
منشور في: (2023-09-01)

Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study
حسب: Seyed Ali Mirshahvalad, وآخرون
منشور في: (2023-01-01)

COMPARISON OF 18F-FDG AND 18F-PSMA PET/CT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
حسب: Najua Abou Arabi Silveira, وآخرون
منشور في: (2024-04-01)

<sup>177</sup>Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α<sub>1</sub>-Microglobulin (A1M), Including Kidney Damage Assessment Using <sup>99m</sup>Tc-MAG3 Imaging
حسب: Amanda Kristiansson, وآخرون
منشور في: (2021-02-01)

Imageological/Structural Study regarding the Improved Pharmacokinetics by <sup>68</sup>Ga-Labeled PEGylated PSMA Multimer in Prostate Cancer
حسب: Huihui Zhang, وآخرون
منشور في: (2023-04-01)

Diagnostic Role of <sup>18</sup>F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
حسب: Salam Awenat, وآخرون
منشور في: (2021-03-01)

PSMA-Directed Theranostics in Prostate Cancer
حسب: Salman Ayub Jajja, وآخرون
منشور في: (2025-07-01)

Paving the way for future PSMA inhibitors: insights from comparative preclinical evaluations of structure modifications
حسب: Katarína Hajduová, وآخرون
منشور في: (2025-09-01)

PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues
حسب: Seiji Hoshi, وآخرون
منشور في: (2023-08-01)

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
حسب: Fanny Lundmark, وآخرون
منشور في: (2020-07-01)

<sup>64</sup>CuCl<sub>2</sub> PET Imaging of 4T1-Related Allograft of Triple-Negative Breast Cancer in Mice
حسب: Adrien Latgé, وآخرون
منشور في: (2022-07-01)

Parathyroid Adenoma Detected in <sup>68</sup>Ga-PSMA PET/CT but Not in the Dedicated Imaging Modalities
حسب: Maja Cieślewicz, وآخرون
منشور في: (2024-08-01)